Cellaïon
We Care for the Liver,
We Care for
Lives
Cell Signaling Technology
for Liver Repair
& Organ Regeneration
Vision
Cellaïon is a Belgian biotechnology company developing life-saving advanced therapies that aim to repair tissues and regenerate organs, particularly the liver. Cellaïon targets life-threatening diseases.
Mission
We, at Cellaïon, are developing HepaStem® with an aim to restore the human body’s regenerative process and to support the survival of a failing native liver
What we do
We aim to repair tissues and regenerate organs using cell signaling technology
Our prime target is the liver space. The liver is a critical organ of the body that is responsible for an array of functions. Any downfall of its functioning leads to failure of other vital organs and ultimately death.
With HepaStem®, Cellaïon aims to stop the progression of chronic liver disease, control inflammation, stop fibrous tissue accumulation in the liver and eventually allow recovery and regeneration of the liver.
Pipeline
Clinical Trial / Publication
A phase II study of human allogeneic liver-derived progenitor cell therapy for acute-on-chronic liver failure and acute decompensation.
Published in April 2021 in JHEP Liver
News & Events
Explore our selection of research articles and news
Cellaïon News
Cellaïon Announces Discontinuation of Phase 2b Clinical Trial in Acute on Chronic Liver Failure with HepaStem®
Cellaïon News
Cellaïon SA appoints new Chief Executive Officer to drive Clinical & Commercial development
Cellaïon News
Cellaïon SA announces an additional closing of 5,5M Euros financing on June 13th 2023.